Xiao Jianbo, Luo Kexin, Liu Meihan, Zhao Haiyang, Cai Yuanze, Gui Yan, Zhang Hongpan
Affiliated Hospital of North Sichuan Medical College, Nanchong, People's Republic of China.
Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People's Republic of China.
Biochem Genet. 2025 Aug 13. doi: 10.1007/s10528-025-11224-x.
Lung cancer is a common and highly lethal malignancy globally, predominantly comprising non-small cell lung cancer (NSCLC), accounting for 80-85% of lung cancer cases. Lung adenocarcinoma (LUAD) represents the predominant subtype of NSCLC and is characterized by challenging early diagnosis and poor prognosis. Studies have implicated CBFA2T3 expression in treatment outcomes and prognosis across various cancers, yet its specific mechanisms remain under investigation. Analysis of TCGA data revealed a negative correlation between CBFA2T3 expression and tumor growth, suggesting that lower CBFA2T3 levels are associated with poorer outcomes in patients with LUAD. Our research identifies CBFA2T3 as a therapeutic target and potential prognostic indicator in LUAD, closely linked to immune cell infiltration and key immune regulatory markers. A model integrating CBFA2T3-regulated immune-related genes was constructed to predict the prognosis and immunotherapy response of patients with LUAD. Our findings were validated using GSE31210 and IMvigor210 datasets. qPCR and WB experiments on clinically collected samples confirmed reduced CBFA2T3 expression in LUAD. Online analysis using the Kaplan‒Meier plotter website confirmed a correlation between reduced CBFA2T3 expression and poorer prognosis in patients with lung cancer. Ultimately, our study identifies CBFA2T3 as a pivotal prognostic biomarker and potential therapeutic target for managing LUAD.
肺癌是全球常见且极具致死性的恶性肿瘤，主要包括非小细胞肺癌（NSCLC），占肺癌病例的80-85%。肺腺癌（LUAD）是NSCLC的主要亚型，其特点是早期诊断具有挑战性且预后较差。研究表明CBFA2T3的表达与多种癌症的治疗结果和预后有关，但其具体机制仍在研究中。对TCGA数据的分析显示CBFA2T3表达与肿瘤生长呈负相关，这表明CBFA2T3水平较低与LUAD患者的预后较差有关。我们的研究确定CBFA2T3是LUAD的治疗靶点和潜在的预后指标，与免疫细胞浸润和关键免疫调节标志物密切相关。构建了一个整合CBFA2T3调节的免疫相关基因的模型，以预测LUAD患者的预后和免疫治疗反应。我们的研究结果在GSE31210和IMvigor210数据集上得到了验证。对临床收集样本进行的qPCR和WB实验证实LUAD中CBFA2T3表达降低。使用Kaplan-Meier plotter网站进行的在线分析证实CBFA2T3表达降低与肺癌患者预后较差之间存在相关性。最终，我们的研究确定CBFA2T3是管理LUAD的关键预后生物标志物和潜在治疗靶点。
